Literature DB >> 10954539

Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture.

R H Archer1, C Dykes, P Gerondelis, A Lloyd, P Fay, R C Reichman, R A Bambara, L M Demeter.   

Abstract

Three mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (V106A, V179D, and Y181C), which occur in clinical isolates and confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), were analyzed for RNA- and DNA-dependent DNA polymerization and RNase H cleavage. All mutants demonstrated processivities of polymerization that were indistinguishable from wild-type enzyme under conditions in which deoxynucleoside triphosphates were not limiting. The V106A reverse transcriptase demonstrated a three- to fourfold slowing of both DNA 3'-end-directed and RNA 5'-end-directed RNase H cleavage relative to both wild-type and V179D enzymes, similar to what was observed for P236L in a previously published study (P. Gerondelis et al., J. Virol. 73:5803-5813, 1999). In contrast, the Y181C reverse transcriptase demonstrated a selective acceleration of the secondary RNase H cleavage step during both modes of RNase H cleavage. The relative replication fitness of these mutants in H9 cells was assessed in parallel infections as well as in growth competition experiments. Of the NNRTI-resistant mutants, V179D was more fit than Y181C, and both of these mutants were more fit than V106A, which demonstrated the greatest reduction in RNase H cleavage. These findings, in combination with results from previous work, suggest that abnormalities in RNase H cleavage are a common characteristic of HIV-1 mutants resistant to NNRTIs and that combined reductions in the rates of DNA 3'-end- and RNA 5'-end-directed cleavages are associated with significant reductions in the replication fitness of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954539      PMCID: PMC116350          DOI: 10.1128/jvi.74.18.8390-8401.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  Interaction of retroviral reverse transcriptase with template-primer duplexes during replication.

Authors:  E J Arts; S F Le Grice
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1998

2.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.

Authors:  R M Esnouf; J Ren; A L Hopkins; C K Ross; E Y Jones; D K Stammers; D I Stuart
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

3.  Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  N K Back; B Berkhout
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Alanine-scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity.

Authors:  M D Powell; M Ghosh; P S Jacques; K J Howard; S F Le Grice; J G Levin
Journal:  J Biol Chem       Date:  1997-05-16       Impact factor: 5.157

5.  HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.

Authors:  L M Demeter; P M Meehan; G Morse; P Gerondelis; A Dexter; L Berrios; S Cox; W Freimuth; R C Reichman
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-02-01

6.  Mutating a conserved motif of the HIV-1 reverse transcriptase palm subdomain alters primer utilization.

Authors:  M Ghosh; J Williams; M D Powell; J G Levin; S F Le Grice
Journal:  Biochemistry       Date:  1997-05-13       Impact factor: 3.162

7.  Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.

Authors:  M Hsu; P Inouye; L Rezende; N Richard; Z Li; V R Prasad; M A Wainberg
Journal:  Nucleic Acids Res       Date:  1997-11-15       Impact factor: 16.971

8.  A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation.

Authors:  N Fan; K B Rank; D E Slade; S M Poppe; D B Evans; L A Kopta; R A Olmsted; R C Thomas; W G Tarpley; S K Sharma
Journal:  Biochemistry       Date:  1996-07-30       Impact factor: 3.162

9.  Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function.

Authors:  C Palaniappan; M Wisniewski; P S Jacques; S F Le Grice; P J Fay; R A Bambara
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

10.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

View more
  42 in total

1.  Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.

Authors:  Nikolaos Chatziandreou; Ana Belen Arauz; Ines Freitas; Phyu Hninn Nyein; Gregory Fenton; Shruti H Mehta; Gregory D Kirk; Manish Sagar
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-25       Impact factor: 2.205

2.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Authors:  Jiong Wang; Robert A Bambara; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

5.  Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.

Authors:  Carrie Dykes; Jiong Wang; Xia Jin; Vicente Planelles; Dong Sung An; Amanda Tallo; Yangxin Huang; Hulin Wu; Lisa M Demeter
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

6.  Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Authors:  Christine E Koval; Carrie Dykes; Jiong Wang; Lisa M Demeter
Journal:  Virology       Date:  2006-06-21       Impact factor: 3.616

7.  Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.

Authors:  Marc Wirden; Anne Simon; Luminita Schneider; Roland Tubiana; Luc Paris; Anne Genevieve Marcelin; Constance Delaugerre; Mayeule Legrand; Serge Herson; Gilles Peytavin; Christine Katlama; Vincent Calvez
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

8.  Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.

Authors:  John M Muchiri; Dongge Li; Carrie Dykes; Robert A Bambara
Journal:  Biochemistry       Date:  2013-07-09       Impact factor: 3.162

9.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

10.  Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.

Authors:  Giada A Locatelli; Giuseppe Campiani; Reynel Cancio; Elena Morelli; Anna Ramunno; Sandra Gemma; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.